Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Two medications have transformed how millions approach weight management: semaglutide, a GLP-1 receptor agonist, and tirzepatide, which activates both GLP-1 and GIP receptors simultaneously. Clinical trials show tirzepatide produces numerically greater weight reduction in some patients, yet individual response varies significantly based on genetic predisposition and metabolic factors. PlexusDx offers compounded versions of both medications through licensed 503A pharmacies, plus genetic testing to identify which pathway may work best for your body.

How Tirzepatide and Semaglutide Work Differently

Semaglutide activates GLP-1 receptors in the brain, pancreas, and gut, triggering satiety signals and slowing gastric emptying. This single-receptor approach has demonstrated consistent weight loss across diverse populations. Tirzepatide activates both GLP-1 and GIP receptors, creating a dual-hormone effect that influences appetite centers, insulin secretion, and metabolic rate through two independent signaling pathways.

The GIP receptor, dormant in earlier GLP-1-only therapies, appears to amplify weight loss through enhanced insulin sensitivity and increased energy expenditure. Some patients experience superior results with tirzepatide's dual mechanism, while others respond equally well to semaglutide's established, single-pathway approach. Individual genetic variation in GLP1R and GIPR gene expression significantly influences which medication produces optimal outcomes for your metabolism.

Clinical Evidence: Weight Loss Outcomes and Trial Data

The SURMOUNT clinical trial program demonstrated that tirzepatide at maximum doses produced average weight reductions of 21-23% of baseline body weight over 72 weeks, compared to semaglutide's average reductions of 14-17% in direct comparison studies. However, these aggregate numbers mask substantial individual variability—some semaglutide users achieve 20%+ weight loss, while others on tirzepatide see more modest results. Baseline metabolic factors, adherence patterns, and lifestyle integration strongly influence real-world outcomes.

Beyond weight loss, both medications improve glycemic control and cardiovascular markers in clinical populations. Tirzepatide shows slightly stronger improvements in fasting insulin levels and HbA1c reduction, reflecting its dual-receptor mechanism. Neither medication is appropriate for all patients, and genetic predisposition to respond to each pathway varies substantially across individuals, which is why personalized assessment matters.

Side Effect Profiles and Tolerability Considerations

Gastrointestinal side effects—nausea, vomiting, constipation, and diarrhea—occur with both medications but may differ in frequency and severity between individuals. Semaglutide's longer track record (approved by the FDA since 2017 for diabetes) provides more robust real-world safety data across millions of users. Tirzepatide, approved more recently, has shown comparable safety profiles in clinical trials, though longer-term data in diverse populations continues to accumulate.

Dose escalation timing influences tolerability; PlexusDx compounds both medications with flexible dosing schedules that allow gradual titration to minimize GI disruption. Injection-based formulations bypass first-pass metabolism, potentially reducing gastrointestinal side effects compared to some oral formulations. Individual tolerance depends on gut microbiome composition, baseline GI sensitivity, and concurrent medications—factors worth discussing with your PlexusDx clinical team.

Cost and Access: Compounded Tirzepatide and Semaglutide Through PlexusDx

PlexusDx offers compounded semaglutide injection starting at $149/month and tirzepatide injection starting at $249/month, with pricing that remains flat regardless of your dose level—your dose may need to go up, but your price won't. Both medications are prepared by licensed 503A compounding pharmacies and shipped to all 50 states without requiring insurance, membership fees, or prior authorization. HSA and FSA accounts are eligible payment methods, reducing out-of-pocket costs for many patients.

For patients seeking a dual-compound approach, PlexusDx offers GLP-Squared Injection (a combination formulation of semaglutide and tirzepatide) starting at $249/month, allowing exploration of synergistic receptor activation in a single administration. The Precision Peptide Genetic Test ($99 add-on after your first month) maps 14 metabolic pathways and 49 peptides to identify whether your genetic profile predicts stronger response to GLP-1-only or GLP-1/GIP dual mechanisms, personalizing your therapy selection.

Personalizing Your Choice: Genetic Testing and Metabolic Profiling

Genetic variation in the GLP1R gene (including rs6923761) and GIPR gene (rs1800437) influences receptor density and signaling efficiency in appetite-regulating brain regions. Patients carrying specific GLP1R variants may achieve greater weight loss on semaglutide alone, while those with GIPR-favorable genotypes often respond more dramatically to tirzepatide's dual activation. The PlexusDx Precision Peptide Genetic Test examines these and 148+ additional genetic insights to predict your individual peptide-pathway responsiveness.

Beyond receptor genetics, variants in FTO (rs9939609) and MC4R (rs17782313) genes reflect predisposition to metabolic challenges and appetite dysregulation severity. Patients with high-risk FTO variants often benefit from more aggressive dual-hormone therapy, while those with favorable genetic profiles may achieve excellent results on either medication. Combining genetic data with clinical history, lifestyle capacity, and baseline metabolic markers creates a personalized treatment algorithm rather than a one-size-fits-all approach.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which medication causes more weight loss: tirzepatide or semaglutide?

Clinical trials show tirzepatide produces slightly greater average weight loss (21-23%) compared to semaglutide (14-17%), but individual results vary dramatically based on genetics and lifestyle. Some patients achieve superior outcomes on semaglutide, while others respond best to tirzepatide's dual-receptor mechanism. PlexusDx Precision Peptide Genetic Testing identifies which pathway aligns with your genetic predisposition.

What is the GIP receptor and why does it matter for weight loss?

GIP (glucose-dependent insulinotropic polypeptide) is a hormone receptor that, when activated alongside GLP-1, enhances insulin sensitivity, reduces appetite, and increases energy expenditure. Tirzepatide's dual GLP-1/GIP activation produces amplified metabolic effects in some patients. Genetic variation in the GIPR gene determines whether you'll experience significant benefit from this dual mechanism or respond equally well to GLP-1-only therapy.

How much does compounded tirzepatide cost at PlexusDx?

Compounded tirzepatide injection starts at $249/month and remains flat regardless of dose escalation. PlexusDx ships to all 50 states without insurance requirements, and the medication is HSA/FSA-eligible. Pricing transparency means your cost won't increase as your clinician optimizes your dose for maximum benefit.

Are compounded semaglutide and tirzepatide safe?

Both medications are compounded by licensed 503A pharmacies under strict pharmaceutical standards. Safety profiles are comparable to branded versions, with gastrointestinal side effects being most common during dose escalation. PlexusDx clinical teams monitor your tolerance and adjust dosing schedules to minimize discomfort while maintaining efficacy.

Can the Precision Peptide Genetic Test predict which medication I should use?

Yes. The PlexusDx Precision Peptide Genetic Test examines GLP1R, GIPR, FTO, and MC4R variants alongside 45 additional peptide-pathway markers to predict your response profile. This peptide-pathway genetic testing (not pharmacogenomic testing) identifies whether you're positioned for stronger response to semaglutide, tirzepatide, or a dual-compound approach—personalizing your therapy selection.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves